Health Digital Twins are moving closer to clinical drug development in oncology.

This work brings together expertise from Fortrea, TwinEdge Biosciences, Imperial College London, the University of Lausanne, Cambridge University Hospitals and Pathway Bio to explore how Health Digital Twins can contribute to the next generation of oncology clinical trials.

The paper discusses how Digital Twins could support:

• better biological and molecular stratification of patients
• in-silico exploration of treatment strategies
• cohort and dose selection in early clinical development
• synthetic control arms and adaptive trial designs
• more predictive and data-driven clinical development

At TwinEdge Biosciences, this is particularly relevant to our vision of creating patient-specific Digital Avatars capable of translating molecular information into predictive models of treatment response.

Combining this modelling approach with Fortrea’s expertise in clinical drug development illustrates an important opportunity: bringing computational patient models closer to real-world clinical development and ultimately helping design more efficient and more personalized oncology trials.

A great collaborative effort, and an important step toward making Digital Twins a practical component of model-informed drug development.